NHRI-NCKU Co-originated Drug Candidate DBPR168 Reaches Major Clinical Milestone with First Participant Dosed in Phase I Trial
DBPR168, a neuroprotective drug candidate jointly …
分類: News & Events
NHRI and NCKU Collaborate on Tech Transfer: Neuroprotective Candidate DBPR168 Receives US FDA IND Clearance
The neuroprotective candidate drug DBPR168, jointl…
Open Tenure-Track Faculty Positions in Medicinal Chemistry & AI Drug Discovery, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (NHRI), Taiwan
National Health Research Institutes Institute of B…
NHRI Has Signed the Technology Transfer Agreement With AnBogen Therapeutics for DBPR376
National Health Research Institutes (NHRI) and AnB…
The National Health Research Institutes have written a new chapter in drug development in Taiwan
Diabetes drug DBPR108 granted New Drug Approval
According to market research reports, the global d…
NMPA Accepted New Drug Application for DBPR108
NHRI announced that the National Medical Products …
DBPR22998: A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRPα Axis for Cancer Immunotherapy
CD47-SIRPα “Do-not-eat- me” signaling axis is myel…
Novel AXL and MERTK Dual Kinase Inhibitor as Anti-Tumor and Immunomodulatory Agent
During the past two decades, the paradigm for canc…
NHRI Enters Technology Transfer Agreement of DBPR186 with Taivex Therapeutics Corp.
National Health Research Institutes (NHRI) and Tai…
NHRI Enters Technology Transfer Agreement of DBPR114 with LaunXP Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Lau…
NHRI and NCKU Collaborate on Tech Transfer: Neuroprotective Candidate DBPR168 Receives US FDA IND Clearance
The neuroprotective candidate drug DBPR168, jointl…
Open Tenure-Track Faculty Positions in Medicinal Chemistry & AI Drug Discovery, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (NHRI), Taiwan
National Health Research Institutes Institute of B…
NHRI Has Signed the Technology Transfer Agreement With AnBogen Therapeutics for DBPR376
National Health Research Institutes (NHRI) and AnB…
The National Health Research Institutes have written a new chapter in drug development in Taiwan
Diabetes drug DBPR108 granted New Drug Approval
According to market research reports, the global d…
NMPA Accepted New Drug Application for DBPR108
NHRI announced that the National Medical Products …
DBPR22998: A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRPα Axis for Cancer Immunotherapy
CD47-SIRPα “Do-not-eat- me” signaling axis is myel…
Novel AXL and MERTK Dual Kinase Inhibitor as Anti-Tumor and Immunomodulatory Agent
During the past two decades, the paradigm for canc…
NHRI Enters Technology Transfer Agreement of DBPR186 with Taivex Therapeutics Corp.
National Health Research Institutes (NHRI) and Tai…
NHRI Enters Technology Transfer Agreement of DBPR114 with LaunXP Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Lau…